Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0779
    -0.0014 (-0.13%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0000 (-0.00%)
     
  • USD/JPY

    151.3770
    +0.0050 (+0.00%)
     
  • Bitcoin USD

    70,249.15
    +482.80 (+0.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,338.04
    +169.97 (+0.42%)
     

Xeris Pharma, Tetris Ink Commercialization Pact For Ogluo In Europe

  • Xeris Pharmaceuticals Inc (NASDAQ: XERS) has entered into an exclusive agreement with Tetris Pharma Limited to commercialize Ogluo in the European Economic Area, the U.K., and Switzerland.

  • Ogluo is indicated to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus.

  • Xeris will be responsible for product supply, and Tetris will be responsible for the commercialization of Ogluo in the Territory.

  • Xeris will receive up to $71 million in payments tied to the first commercial sale and other related milestone payments and collect a royalty on net sales.

  • The Company expects to launch Ogluo in the U.K. by the end of 2021 and at least seven additional countries by mid-2022.

  • Xeris estimates there are more than five million patients on insulin and at risk of severe hypoglycemia in the Territory, with only an estimated 10-20% having a prescription for glucagon.

  • Price Action: XERS shares are down 1.30% at $3.42 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement